1
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, S Tarran Jones, Ted A Yednock: Humanized antibodies against leukocyte adhesion molecule VLA-4. Athena Neurosciences, Townsend & Townsend & Crew, November 24, 1998: US05840299 (86 worldwide citation)

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.


2
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O&apos Brien, Theresa O&apos Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, February 24, 2004: US06696550 (40 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


3
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, December 12, 2006: US07147851 (32 worldwide citation)

The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In on ...


4
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O&apos Brien, Theresa O&apos Keefe: Recombinant anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, April 27, 2004: US06727349 (29 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


5
Tarran Jones
Robert W Chestnut, Margaret J Polley, James C Paulson, S Tarran Jones, Jose W Saldanha, Mary M Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn: Antibodies to P-selectin and their uses. Cytel Corporation, Campbell & Flores, September 1, 1998: US05800815 (24 worldwide citation)

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


6
Tarran Jones
Gregory J LaRosa, Christopher J Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lando & Anastasi, July 28, 2009: US07566450 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


7
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lowrie Lando & Anastasi, January 6, 2009: US07473421 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


8
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lowrie Lando & Anastasi, October 28, 2008: US07442775 (4 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


9
Tarran Jones
Robert W Chesnut, Margaret J Polley, James C Paulson, S Tarran Jones, Jose W Saldanha, Mary M Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn: Method for detecting the presence of P-selectin. Cytel Corporation, Campbell & Flores, March 7, 2000: US06033667 (4 worldwide citation)

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


10
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lando & Anastasi, July 24, 2012: US08227211 (3 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...